First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictorRuth Plummer(Freeman Hospital), Debashis Sarker(King's College London)British Journal of CancerJune 10, 202010.1038/s41416-020-0916-5Cited by 76SaveCiteExport RISWatch citationsRelated PapersTIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors|Cell Reports Medicine|2025|11